These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 26239034)
1. Impact of the thickness of the subcutaneous tissue at the site of injection as measured by ultrasound on the therapeutic response to subcutaneous anti-tumor necrosis factor drugs. Del Río T; Valor L; de la Torre I; Naredo E Reumatol Clin; 2016; 12(5):300-1. PubMed ID: 26239034 [No Abstract] [Full Text] [Related]
2. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Del Porto F; Laganà B; Lai S; Nofroni I; Tinti F; Vitale M; Podestà E; Mitterhofer AP; D'Amelio R Rheumatology (Oxford); 2007 Jul; 46(7):1111-5. PubMed ID: 17449484 [TBL] [Abstract][Full Text] [Related]
3. Golimumab (simponi) for inflammatory arthritis. Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489 [No Abstract] [Full Text] [Related]
4. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061 [TBL] [Abstract][Full Text] [Related]
5. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663 [TBL] [Abstract][Full Text] [Related]
6. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study. Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585 [TBL] [Abstract][Full Text] [Related]
7. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583 [TBL] [Abstract][Full Text] [Related]
9. [Basic therapeutic and immunosuppressive drugs in rheumatoid arthritis. No fear of "heavy weapons"]. Krüger K MMW Fortschr Med; 2002 Aug; 144(33-34):25-30. PubMed ID: 12380140 [No Abstract] [Full Text] [Related]
10. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment? Dayer JM; Krane SM N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Benucci M; Saviola G; Baiardi P; Manfredi M; Sarzi-Puttini P; Atzeni F Int J Immunopathol Pharmacol; 2011; 24(1):269-74. PubMed ID: 21496415 [TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373 [TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU; Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810 [TBL] [Abstract][Full Text] [Related]
14. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718 [TBL] [Abstract][Full Text] [Related]